This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

According to GlobalData’s estimates, based on reported revenues, GE Healthcare, Philips Healthcare and Siemens Healthcare account for 87% of the APAC PET and SPECT nuclear imaging market. This can be attributed to product portfolio offerings within nuclear imaging and the wide geographic reach of these companies. These companies are large engineering conglomerates that are able to leverage considerable financial and engineering resources to develop and market capital-intensive premium equipment. In addition, the strong financial positions of these companies ensures that they can also grow inorganically within the segment, and remain technologically competitive. In addition, KOLs indicated that the companies’ high market share is also due to the strong support services they provide, enabling them to become the preferred vendors of most facilities.

Scope

• An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized APAC Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Nuclear Imaging
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving APAC Nuclear Imaging market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in APAC Nuclear Imaging market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in APAC Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 6
1.1 List of Tables 12
1.2 List of Figures 15

2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 18

3 Industry Overview 19
3.1 Nuclear Imaging Techniques 19
3.1.1 Positron Emission Tomography 19
3.1.2 Single-Photon Emission Computed Tomography 21
3.1.3 Planar Scintigraphy 21
3.1.4 Hybrid Imaging 22
3.2 Clinical Applications of Nuclear Imaging Technology 27
3.2.1 Cancer 27
3.2.2 Cardiology 29
3.2.3 Neurology 31
3.2.4 Infection and Inflammation 33
3.3 Advantages and Disadvantages of Nuclear Imaging Technologies 36
3.4 Market Access 37
3.4.1 Product Life Cycle 37
3.4.2 Purchasing Decisions 39
3.4.3 Equipment Leasing 45
3.4.4 Replacement of PET/CT by PET/MRI 45
3.5 Reimbursement 50
3.5.1 Overview 50
3.5.2 Japan 51
3.5.3 China 51
3.5.4 India 52
3.6 Procedure Trends 53
3.6.1 Japan 53
3.6.2 China 55
3.6.3 India 57
3.7 Regulatory Issues/Recalls 60
3.8 M&As and Key Partnerships 61
3.9 Economic Impact 64

4 Unmet Needs 68
4.1 Overview 68
4.2 Improved Reimbursement for New Techniques 68
4.3 Lack of Binding Clinical Guidelines 72
4.4 Patient Comfort and Convenience 72
4.5 Reducing Radiation Exposure 73
4.6 Improved Scanner Performance 75
4.7 Image Processing Software Improvements 76
4.8 Increased Risk of Artifacts in Hybrid Images 78
4.9 Demand for New Radiotracers 79
4.10 Improved Clinical Input into the Design Process 81

5 Market Opportunity Analysis 82
5.1 Cheaper, Simpler Nuclear Imaging Devices 82
5.2 SPECT/CT in Developing Countries 82
5.3 Increased Demand for Teleradiology Services 85

6 Market Drivers and Barriers 87
6.1 Driver: Aging Population and Increasing Disease Prevalence 87
6.2 Driver: Referring Physician Awareness 88
6.3 Driver: Defensive medicine 89
6.4 Driver: Patient Awareness 91
6.5 Driver: Self-Referral 91
6.6 Driver: New Imaging Agents 92
6.7 Driver: Increasing Demand for Cancer Diagnostic Tests 92
6.8 Driver: Companion Diagnostic Testing 93
6.9 Barrier: Comparative Effectiveness Research 94
6.10 Barrier: Reimbursement Legislation 96
6.11 Barrier: Increasing Demand for Nuclear Imaging in Developing Markets 96
6.12 Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging 98
6.13 Barrier: Greater Payer Scrutiny of EMRs 98
6.14 Barrier: Increased Use of Appropriateness Criteria 99
6.15 Barrier: Practice Guidelines to Reduce Unnecessary Procedures 101
6.16 Barrier: Imaging Facility Accreditation 101
6.17 Barrier: Loss of Nuclear Medicine Skills 102
6.18 Barrier: High Cost of Instruments and Reagents 103
6.19 Barrier: Radiopharmaceutical Cost and Supply Difficulties 104
6.20 Barrier: Hospital Consolidation 107

7 Competitive Assessment 108
7.1 Overview 108
7.2 Dedicated PET Systems 108
7.2.1 Overview 108
7.2.2 Product Profile 109
7.2.3 SWOT Analysis 110
7.3 PET/CT Systems 110
7.3.1 Overview 110
7.3.2 Product Profiles 111
7.3.3 SWOT Analysis 113
7.4 PET/MRI Systems 113
7.4.1 Overview 113
7.4.2 Product Profile 115
7.4.3 SWOT Analysis 116
7.5 Dedicated SPECT Systems 116
7.5.1 Overview 116
7.5.2 Product Profile 118
7.5.3 SWOT Analysis 119
7.6 SPECT/CT Systems 120
7.6.1 Overview 120
7.6.2 Product Profile 122
7.6.3 SWOT Analysis 123
7.7 PET/Ultrasound and SPECT/Ultrasound Systems 124
7.7.1 Overview 124
7.7.2 Product Profile 124
7.7.3 SWOT Analysis 125

8 Pipeline Assessment 126
8.1 Overview 126
8.2 Pipeline by Phases in Development 127
8.3 Product Profiles 127
8.3.1 Brain Biosciences CerePET 127
8.3.2 ECORAD Dual Modality Imager 129
8.3.3 FMI Technologies ScintiStar PET/CT 130
8.3.4 IntraMedical Imaging Marginator Beta Camera 132
8.3.5 INSERT SPECT/MRI 133
8.3.6 Nucare/Zecotek Photonics New Generation PET Scanning Device 136
8.3.7 Philips Healthcare PET Alpha Ring Detector 137
8.3.8 Photo Diagnostic Systems NeuroPET/CT 138
8.3.9 SynchroPET Breast PET/MRI 139
8.3.10 SynchroPET Wrist Scanner 140
8.3.11 SurgicEye SPECT Hybrid 141

9 Clinical Trials to Watch 143
9.1 Overview 143
9.2 Clinical Trial Profiles 143

10 Current and Future Players 146
10.1 Overview 146
10.2 Trends in Corporate Strategy 146
10.3 Company Profiles 147
10.3.1 DDD-Diagnostic 147
10.3.2 Digirad 149
10.3.3 GE Healthcare 153
10.3.4 GVI Medical Devices 158
10.3.5 Mediso Medical Imaging Systems 160
10.3.6 NeuroLogica 162
10.3.7 Neusoft Medical Systems 165
10.3.8 NuCare Medical Systems 168
10.3.9 Oncovision 170
10.3.10 Philips Healthcare 172
10.3.11 Shimadzu 179
10.3.12 Siemens Healthcare 184
10.3.13 SurgicEye 190
10.3.14 Toshiba Medical 193
10.3.15 Other Companies 198

11 Market Outlooks 201
11.1 Company Market Share Analysis 201
11.1.1 APAC Region Overview 201
11.1.2 Japan 202
11.1.3 China 202
11.1.4 India 203
11.2 Market Segment Share 204
11.2.1 SPECT & SPECT/CT 204
11.2.2 PET, PET/CT & PET/MRI 205
11.3 By Geography 207
11.3.1 APAC Region Overview 207
11.3.2 Japan 209
11.3.3 China 211
11.3.4 India 214

12 Appendix 217
12.1 Abbreviations 217
12.2 Bibliography 221
12.3 Methodology 248
12.3.1 Overview 248
12.3.2 Coverage 249
12.3.3 Secondary Research 249
12.4 Physicians and Specialists Included in This Study 251
12.5 Primary Research 252
12.5.1 Primary Research - Key Opinion Leader Interviews 252
12.5.2 Expert Panel Validation 253
12.5.3 Stakeholder Survey 254
12.6 Forecasting Methodology 256
12.7 About the Authors 257
12.7.1 Andrew Thompson, PhD, Senior Analyst 257
12.7.2 Priya Radhakrishnan, MBA, Director, Medical Devices 257
12.7.3 Bonnie Bain, PhD, Global Head of Healthcare 258
12.8 About GlobalData 259
12.9 Disclaimer 259

List of Tables

Table 1: Applications of Nuclear Imaging 27
Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers 28
Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology 31
Table 4: Applications of PET Imaging in Non-Cancer Neurology 32
Table 5: Applications of SPECT Imaging in Non-Cancer Neurology 32
Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI 37
Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009 38
Table 8: Nuclear Imaging Trends in Japan, 2012-2020 54
Table 9: Nuclear Imaging Trends in China 2012-2020 57
Table 10: Nuclear Imaging Trends in India, 2012-2020 59
Table 11: Recent Device Recalls in the Nuclear Imaging Market 61
Table 12: Recent Key Events in the Nuclear Imaging Market 63
Table 13: Nuclear Imaging Market Drivers and Barriers 87
Table 14: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US 99
Table 15: Dedicated PET Scanners 109
Table 16: Dedicated PET SWOT Analysis 110
Table 17: PET/CT Scanners 111
Table 18: PET/CT SWOT Analysis 113
Table 19: PET/MRI Systems 115
Table 20: PET/MRI SWOT Analysis 116
Table 21: Dedicated SPECT Systems 118
Table 22: Dedicated SPECT SWOT Analysis 119
Table 23: SPECT/CT Systems 122
Table 24: SPECT/CT SWOT Analysis 123
Table 25: SPECT-Ultrasound Systems 124
Table 26: SPECT/Ultrasound SWOT Analysis 125
Table 27: Nuclear Imaging Pipeline, 2014 127
Table 28: CerePET SWOT Analysis 129
Table 29: ECORAD Dual Modality Imager SWOT Analysis 130
Table 30: ScintiStar PET/CT SWOT Analysis 132
Table 31: Marginator SWOT Analysis 133
Table 32: INSERT SPECT-MRI SWOT Analysis 136
Table 33: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis 137
Table 34: PET Alpha Ring Detector 138
Table 35: NeuroPET/CT Scanner SWOT Analysis 139
Table 36: SynchroPET Breast PET/MRI SWOT Analysis 140
Table 37: SynchroPET Wrist Scanner 141
Table 38: SurgicEye SPECT/Ultrasound device SWOT Analysis 142
Table 39: Key Clinical Trials 144
Table 40: Company Profile - DDD-Diagnostic 147
Table 41: DDD-Diagnostic SWOT Analysis 149
Table 42: Company Profile - Digirad 150
Table 43: Digirad SWOT Analysis 153
Table 44: Company Profile - GE Healthcare 154
Table 45: GE Healthcare Product Portfolio 155
Table 46: GE Healthcare SWOT Analysis 158
Table 47: Company Profile - GVI Medical Devices 159
Table 48: GVI Medical Devices SWOT Analysis 160
Table 49: Company Profile - Mediso Medical Imaging Systems 161
Table 50: Mediso Medical Imaging Systems SWOT Analysis 162
Table 51: Company Profile - Neurologica 163
Table 52: Neurologica SWOT Analysis 165
Table 53: Company Profile - Neusoft Medical Systems 166
Table 54: Neusoft Medical Systems SWOT Analysis 168
Table 55: Company Profile - NuCare Medical Systems 169
Table 56: Nucare Medical Systems SWOT Analysis 170
Table 57: Company Profile - Oncovision 171
Table 58: Oncovision SWOT Analysis 172
Table 59: Company Profile - Philips Healthcare 173
Table 60: Philips Healthcare SWOT Analysis 179
Table 61: Company Profile - Shimadzu 180
Table 62: Shimadzu SWOT Analysis 184
Table 63: Company Profile - Siemens Healthcare 185
Table 64: Siemens Healthcare SWOT Analysis 190
Table 65: Company Profile - SurgicEye 191
Table 66: SurgicEye SWOT Analysis 193
Table 67: Company Profile - Toshiba Medical 194
Table 68: Toshiba Medical SWOT Analysis 197
Table 69: Other Companies in the Nuclear Imaging Market, 2014 198
Table 70: APAC Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020) 205
Table 71: APAC Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012-2020) 206
Table 72: APAC Sales of PET and SPECT Imaging Systems, 2012-2020 208
Table 73: Japan Market Value Forecast by Market Sub-segment (2012-2020) 209
Table 74: China Market Value Forecast by Market Sub-segment (2012-2020) 212
Table 75: India Market Value Forecast by Market Sub-segment (2012-2020) 214
Table 76: Primary Research Summary 254
Table 77: Primary Research Participants Affiliation 255

List of Figures

Figure 1: Cyclotron Distribution in 10 Countries 20
Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT 24
Figure 3: Mutually Beneficial Effects of PET/MRI Imaging 26
Figure 4: Nuclear Imaging Trends in Japan, 2012-2020 54
Figure 5: Nuclear Imaging Trends in China, 2012-2020 56
Figure 6: SPECT and PET Imaging Trends in India, 2012-2020 59
Figure 7: Total Medicare Expenditures for Imaging Services Paid Under the Physician Fee Schedule, 2000-2006 65
Figure 8: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US 88
Figure 9: APAC Company Market Shares for Nuclear Imaging Equipment (2012) 201
Figure 10: Japan Company Market Shares for Nuclear Imaging Equipment (2012) 202
Figure 11: China Company Market Shares for Nuclear Imaging Equipment (2012) 203
Figure 12: India Company Market Shares for Nuclear Imaging Equipment (2012) 204
Figure 13: APAC Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020) 205
Figure 14: APAC Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012-2020) 207
Figure 15: APAC Sales of PET and SPECT Imaging Systems, 2012-2020 208
Figure 16: Japan Market Value Forecast by Market Sub segment (2012-2020) 210
Figure 17: China Market Value Forecast by Market Sub-segment (2012-2020) 212
Figure 18: India Market Value Forecast by Market Sub segment (2012-2020) 215
Figure 19: Primary Research Summary 254
Figure 20: Primary Research Participants Affiliation 255